These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
876 related articles for article (PubMed ID: 30890542)
1. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program. Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542 [TBL] [Abstract][Full Text] [Related]
2. Detection of Colorectal Neoplasia in a Cohort Before and After the Change of Fecal Occult Blood Test in a French Colorectal Cancer Screening Program. Koïvogui A; Mab GL; Benamouzig R Am J Gastroenterol; 2018 Dec; 113(12):1891-1899. PubMed ID: 30337703 [TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568 [TBL] [Abstract][Full Text] [Related]
4. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499 [TBL] [Abstract][Full Text] [Related]
5. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542 [TBL] [Abstract][Full Text] [Related]
6. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening. Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896 [TBL] [Abstract][Full Text] [Related]
7. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514 [TBL] [Abstract][Full Text] [Related]
8. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Smith A; Young GP; Cole SR; Bampton P Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938 [TBL] [Abstract][Full Text] [Related]
9. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. Singal AG; Corley DA; Kamineni A; Garcia M; Zheng Y; Doria-Rose PV; Quinn VP; Jensen CD; Chubak J; Tiro J; Doubeni CA; Ghai NR; Skinner CS; Wernli K; Halm EA Am J Gastroenterol; 2018 May; 113(5):746-754. PubMed ID: 29487413 [TBL] [Abstract][Full Text] [Related]
10. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community. Hughes K; Leggett B; Del Mar C; Croese J; Fairley S; Masson J; Aitken J; Clavarino A; Janda M; Stanton WR; Tong S; Newman B Aust N Z J Public Health; 2005 Aug; 29(4):358-64. PubMed ID: 16222934 [TBL] [Abstract][Full Text] [Related]
11. Contribution of the OC Sensor Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183 [TBL] [Abstract][Full Text] [Related]
12. Physician-office vs home uptake of colorectal cancer screening using FOBT/FIT among screening-eligible US adults. Chido-Amajuoyi OG; Sharma A; Talluri R; Tami-Maury I; Shete S Cancer Med; 2019 Dec; 8(17):7408-7418. PubMed ID: 31637870 [TBL] [Abstract][Full Text] [Related]
13. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Tinmouth J; Lansdorp-Vogelaar I; Allison JE Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750 [TBL] [Abstract][Full Text] [Related]
14. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test. Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822 [TBL] [Abstract][Full Text] [Related]
15. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting. Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157 [TBL] [Abstract][Full Text] [Related]
16. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients. Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467 [TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016. Almansoori A; Alzaabi M; Alketbi L BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343 [TBL] [Abstract][Full Text] [Related]
18. Participation rates for organized colorectal cancer screening programmes: an international comparison. Klabunde C; Blom J; Bulliard JL; Garcia M; Hagoel L; Mai V; Patnick J; Rozjabek H; Senore C; Törnberg S J Med Screen; 2015 Sep; 22(3):119-26. PubMed ID: 25967088 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive screening for colorectal cancer in Asia. Chiu HM; Chang LC; Hsu WF; Chou CK; Wu MS Best Pract Res Clin Gastroenterol; 2015 Dec; 29(6):953-65. PubMed ID: 26651256 [TBL] [Abstract][Full Text] [Related]
20. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening. Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]